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Background and objective: Several studies have reported an association
between type 2 diabetes mellitus and hepatocellular carcinoma (HCC). Data
from several retrospective studies and meta-analyses have highlighted a
reduction of about 50% in the risk of developing HCC in cirrhotic patients
treated with metformin for diabetes. The aim of this study was to evaluate
the different outcomes of patients who received or did not receive metfor-
min during treatment with sorafenib.
Methods: We analyzed 93 patients consecutively treated with sorafenib.
Forty-two (45.2%) patients were diabetic, of whom 31 were on metformin.
Progression-free survival (PFS) and overall survival (OS) were estimated with
the Kaplan-Meier method and compared with the log-rank test.
Results: The concomitant use of sorafenib and metformin was associated
with a median PFS of 2.6 months (95% CI 1.9–3.3) compared to 5.0 months
(95% CI 2.5–8.2) for patients receiving sorafenib alone (p = 0.029). The
median OS of patients treated with the combination was 10.4 months (95%
CI 3.9–14.4) compared to 15.1 months (95% CI 11.7–17.8) for those who were
not given metformin (p = 0.014).
Conclusions: Our findings could be the result of increased tumor aggressive-
ness and resistance to sorafenib in metformin-treated patients.
Keywords: diabetes, hepatocellular carcinoma, insulin, metformin, sorafenib
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1. Introduction
Each year, >500,000 people worldwide are diagnosed with hepatocellular carci-
noma (HCC), including about 20,000 new cases in the US.[1] It is the fifth most
common cancer and the second most frequent cause of cancer-related death in
men.[2] The incidence of HCC increases progressively with age in all populations,
reaching its peak at 70 years.[3] Medical treatment remains one of the largest
“black holes” in oncology as HCC is one of the most chemoresistant tumors, and
no systemic drug was available for patients with advanced disease until 2007.
Sorafenib, a multikinase inhibitor of the VEGFR, the platelet-derived growth
factor receptor and Raf kinases, has been shown to increase median overall survival
(OS); Llovet et al. reported a median OS of 7.9 months in a placebo group
compared with 10.7 months in patients given sorafenib (hazard ratio
(HR) = 0.69; 95% CI 0.55–0.87; p = 0.00058), representing a 31% decrease in
the relative risk of death.[4]
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Metformin, a biguanide medication commonly used in
patients with diabetes, is known to inhibit the mTOR
pathway through AMP-activated protein kinase (AMPK)
activation. It has also been shown to inhibit tumor
growth in vitro and in vivo by inducing apoptosis in
various malignancies including melanoma [5] and breast
[6] and lung cancer.[7] The results from some retrospec-
tive studies suggest that metformin prevents the develop-
ment of HCC in patients with diabetes [8,9] and in
diabetic patients with chronic liver disease.[10] A large
population-based study by Chen et al. [8] demonstrated a
dose-dependent decrease in the risk of HCC among dia-
betic patients taking metformin, whereas a recent meta-
analysis confirmed a decrease of 50% in the incidence of
HCC among diabetics receiving the drug.[11] It has also
been shown to have a potent tumor-suppressive effect in
other malignancies through AMPK activation and subse-
quent inhibition. Conflicting data have emerged on the
antiangiogenic action of metformin,[12] some studies
indicating that it enhances angiogenesis,[13,14] upregu-
lates VEGF and increases nitric oxide bioavailability in
cardiovascular disease animal models,[15,16] others sug-
gesting that metformin downregulates several angiogen-
esis-related genes.[17]
The aim of our retrospective study was to evaluate the
prognostic significance of metformin in patients with HCC
treated with sorafenib.
2. Patients and methods
2.1 Patient population
This study was done using the medical records databases of
our institute (IRST IRCCS), Università Politecnica delle
Marche; Pisa University Hospital and the National Cancer
Institute of Bari ‘Giovanni Paolo II’. Ninety-three patients
with HCC consecutively treated with sorafenib twice daily
(2 × 200 mg tablets) between March 2008 and August 2014
were included in the study. Patients who had been taking
insulin for at least 5 years at the time of the HCC diagnosis
were considered “patients with diabetes treated with insulin,”
whereas those who had been on metformin at for at least
5 years when HCC was diagnosed were considered “patients
with diabetes treated with metformin.” None of the non-
diabetic patients had ever received metformin. Patients were
monitored closely for toxicity and dose reductions were made
on the basis of type and severity of toxicity. Treatment with
sorafenib was continued until disease progression, unaccep-
table toxicity or death occurred. Disease progression was
assessed using Modified Response Evaluation Criteria in
Solid Tumors criteria.
Data were entered into electronic data files by investiga-
tors from each participating center and were checked by the
data management center (IRST) for missing information
and internal consistency. The study protocol was reviewed
and approved by local Ethics Committees. All patients
provided written informed consent to take part in the study.
2.2 Statistical analysis
Descriptive data were reported as median with range for
continuous variables, and absolute and relative frequencies
for categorical variables. Progression-free survival (PFS) was
calculated from the day of the start of treatment until the day
of documented disease progression or last follow-up. OS was
calculated from the day of the start of treatment until the day
of death or last follow-up. Patients lost to follow-up were
censored at the time of last contact.
PFS, OS and their 95% CI were estimated using the
Kaplan–Meier method and compared with the log-rank
test. Estimated HRs and their 95% CI were calculated
from the Cox proportional hazard regression model. SAS
statistical software version 9.3 (SAS Institute, Cary, NC,
USA) was used for all statistical analyses and a p-value <
0.05 was considered statistically significant.
3. Results
Between March 2008 and August 2014, 93 patients diag-
nosed with HCC were consecutively treated with sorafenib.
The case series comprised 74 men and 19 women with a
median age of 71 years (range 28–87 years). All patients had
Child–Pugh A HCC. Eleven patients had Barcelona Clinic
Liver Cancer Stage B (BCLC-B) HCC and 82 had BCLC-C
HCC. Thirty-five (32.55%) patients had previously under-
gone transarterial chemo embolization (TACE) (Table 1).
Table 1. Patient characteristics.
Characteristic No. patients (%)
Median age, years (range) 71 (28–87)
Sex
Male 74 (79,5)
Female 19 (20,5)
Etiology
Viral 67 (72.0)
Alcoholic 6 (6.5)
NAFLD 13 (14.0)
Other 7 (7.5)
Diabetes
No 51 (54.8)
Yes 42 (45.2)
Antidiabetic drug
Insulin 11 (11.8)
Metformin
None
31 (33.3)
51 (54.9)
ECOG
0 61 (65.5)
1 27 (29.6)
2 5 (5.4)
NAFLD: non-alcoholic fatty liver disease, ECOG: Eastern Cooperative Oncology
Group.
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The most common etiologies of liver disease were hepa-
titis C (34%), alcoholic liver disease (29%), fatty liver
disease (15%) and hepatitis B (9%). Forty-two patients
(45.2%) were diabetic and 31 (33.3%) were receiving
metformin. The case series was homogeneous for age
and sex but not for disease etiology. 25.4% of non-
diabetic patients and 3.2% of diabetic patients were
hepatitis B-positive (Table 2). The median PFS of all
patients was 3.2 months (95% CI: 2.5–5.0) and median
OS was 13.9 months (95 % CI: 10.4–15.8).
The concomitant use of sorafenib and metformin was
associated with a median PFS of 2.6 months (95% CI:
1.9–3.3) compared with 5.0 months (95% CI: 2.5–8.2) for
patients not taking metformin (p = 0.029) (Table 3 and
Figure 1A). Median OS of patients receiving the two drugs
was 10.4 months (95% CI: 3.9–14.4) compared with 15.1
Table 2. Homogeneity of cases analyzed.
No. diabetes (51) Diabetes + metformin (31) Diabetes + insulin (11) p
No. (%) No. (%) No. (%)
Age, years
≤40 2 (3) 0 (0) 0 (0)
>40 ≤ 60 14 (27.4) 5 (16.1) 2 (18.1)
>60 35 (69.6) 26 (83.8) 9 (81.1) 0.257
Sex
Male 35 (68.7) 24 (77.4) 9 (81.8)
Female 16 (31.3) 7 (22.6) 2 (18.2) 0.237
Staging
BCLC B 6 (11.7) 4 (12.9) 1 (9) 0.897
BCLC C 45 (88.3) 27 (87.1) 10 (91)
MELD score 0.954
<10 41 (80.3) 24 (77.4) 9 (81.8)
>10 10 (19.7) 7 (22.6) 2 (18.2)
α-Fetoprotein 0.543
<400 40 (78.4) 22 (70.9) 8 (72.7)
>400 11 (21.6) 9 (29.1) 3 (27.3)
Etiology
Hepatitis C 26 (50.9) 11 (35.4) 4 (36.3)
Hepatitis B 13 (25.4) 1 (3.2) 1 (9)
Alcoholic liver disease 5 (9.8) 7 (22.5) 2 (18.1)
NAFLD 3 (5.8) 10 (32.2) 2 (18.1)
Other 4 (7.8) 2 (6.4) 3 (27.2) 0.012
BCLC: Barcelona Clinic Liver Cancer; NAFLD: non-alcoholic fatty liver disease; MELD: Model for End-Stage Liver Disease.
Table 3. Outcomes related to metformin and sorafenib.
No. patients PFS OS
No. events Median PFS
(95% CI)
p No. events Median OS
(95% CI)
p
Diabetes
No 51 43 3.9 (2.5–6.2) 25 14.9 (11.7–17.8)
Yes 42 37 2.6 (2.0–4.6) 0.226 27 11.2 (5.8–15.8) 0.198
Metformin
No 62 52 5.0 (2.5–8.2) 30 15.1 (11.7–17.8)
Yes 31 28 2.6 (1.9–3.3) 0.029 22 10.4 (3.9–14.4) 0.014
Patients with diabetes treated with
insulin
11 9 10.0 (0.7–18.3) 5 17.6 (2.2-nr)
Patients with diabetes treated with
metformin
31 28 2.6 (1.9–3.3) 0.083 22 10.4 (3.9–14.4) 0.069
OS: overall survival; PFS: progression-free survival.
Metformin and sorafenib in HCC patients
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months (95% CI: 11.7–17.8) for those taking sorafenib only
(p = 0.014) (Table 3 and Figure 1B).
In diabetic patients, the concomitant use of sorafenib and
metformin was associated with a median PFS of 2.6 months
(95% CI: 1.9–3.3) compared with 10.0 months (95% CI:
0.7–18.3) for those taking insulin (p = 0.083) (Table 3 and
Figure 2A). A median OS of 10.4 months (95% CI: 3.9–
14.4) was observed for patients taking sorafenib and metfor-
min compared with 17.6 months (95% CI: 2.2–nr) for those
on insulin (p = 0.069) (Table 3 and Figure 2B).
The concomitant use of TACE and metformin was asso-
ciated with a median PFS of 7.4 months (95% CI: 4.3–15.7)
compared with 11.2 (95% CI: 3.4–15.7) for those not taking
metformin (p = 0.827). Median OS for these groups was
22.0 (95% CI: 13.7–38.9) compared with 43.7 (95% CI:
19.0–nr), respectively (p = 0.05).
Considering the overall population, the risk of progression,
adjusted by age, sex, smoking habits and etiology, was higher
in diabetic patients taking metformin compared with those
who were not diabetic (HR: 2.57; 95% CI: 1.43–4.63;
p = 0.001). Patients with diabetes taking insulin had an
adjusted risk of progression of 0.90 (95% CI: 0.40–2.03;
p = 0.813) compared with non-diabetic cases. Similar results
were observed with regard to survival (HR: 2.32; 95% CI:
1.10–4.90; p = 0.022; and HR: 0.55; 95% CI: 0.18–1.63;
p = 0.295, respectively) (Table 4). Considering diabetic
patients only, the risk of progression, adjusted by age, sex,
smoking habits and etiology, was higher in patients taking
Figure 1. Kaplan–Meier curves of the overall population. (A) Progression-free survival according to metformin treatment. (B)
Overall survival according to metformin treatment. The unbroken line shows patients who did not receive metformin,
whereas the dashed line shows patients who were given metformin in combination with sorafenib. OS: overall survival;
PFS: progression-free survival.
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Figure 2. Kaplan–Meier curves of diabetic patients. (A) Progression-free survival. (B) Overall survival. The unbroken line
shows diabetic patients who received insulin in combination with sorafenib, whereas the dashed line shows diabetic patients
who underwent treatment with metformin and sorafenib. OS: overall survival; PFS: progression-free survival.
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metformin than in those taking insulin (HR: 4.30; 95% CI:
1.30–14.27; p = 0.017). Results were similar for survival
(HR: 5.16; 95% CI: 1.53–17.63; p = 0.008).
4. Discussion
Type 2 diabetes is a significant risk factor for the develop-
ment of malignancies, including HCC.[10,11] Li et al.
recently described a significant linear trend in HCC inci-
dence with increasing glycated hemoglobin levels,[18] but
other authors have reported conflicting data on this.[19–24]
Metformin has garnered considerable interest as a chemopre-
ventive and chemotherapeutic agent given the increased risk
of HCC among patients with insulin resistance.
As far as we know, this is the first work to evaluate the
association between metformin and sorafenib in patients with
HCC. Several studies have shown that metformin decreases
the risk of HCC in patients with cirrhosis.[8,9] We consid-
ered patients who developed HCC during therapy with
metformin and who later received first-line treatment with
sorafenib. From a clinical point of view, metformin did not
enhance the activity of sorafenib. Patients receiving the two-
drug combination showed poorer PFS and OS than those
given sorafenib alone. The overall difference of 2.4 months in
median PFS and 4.7 months in median OS between patients
taking metformin and those not taking metformin was sig-
nificant. Our results also highlighted a distinct, albeit not
significant, advantage in terms of response, PFS and OS in
diabetic patients taking insulin. Larger case series are needed
to confirm these data. The patients analyzed were homoge-
neous for age, sex, stage, score Model for End-Stage Liver
Disease score and basal levels of α-fetoprotein and lactate
dehydrogenase, but not for etiology. Previous studies have
shown a lower activity of sorafenib in HBsAg-positive
patients.[25] Had our case series been homogeneous, the
difference would probably have been greater. We also noted
that response to TACE was not affected by metformin
administration, which confirms that sorafenib-resistant can-
cer clones are generated during the development of HCC in
patients taking metformin.
We do not have information on baseline glucose or
HbA1C levels and this could be a limitation to the
study, but we think that having of well-controlled or not
well-controlled diabetes before sorafenib treatment would not
have made any difference to our results.
Molecular alterations in protein kinases involved in the
molecular action of metformin may lead to a different
response to the sorafenib–metformin combination. The
molecular action of metformin is mainly associated with the
inhibition of the mTOR pathway, which plays an important
role in metabolism, growth and proliferation of cancer cells.
[26] mTOR inhibition may be exerted by metformin
through AMPK activation, which is pivotal in the energy
homeostasis process.[27,28] AMPK is activated through
AMP binding or through phosphorylation by molecular
components such as the liver kinase B1 (LKB1), the ataxia-
telangiectasia mutated (ATM) protein kinase or the calcium
activated kinase (CAMKK2).[29] Although ATM, LKB1 and
AMPK are not the direct targets of metformin, the drug
specifically inhibits mitochondrial respiratory chain complex
I activities,[30] inducing an increase in the cellular AMP:
ATP ratio, which activates AMPK.[30] There is evidence,
however, that metformin also inhibits the mTOR pathway in
an AMPK-independent manner.[6,31] Both AMPK-depen-
dent and -independent pathways are thought to mediate the
anticancer effects of metformin treatment. Moreover, the
antiangiogenic effect of metformin have been attributed to
both AMPK-dependent and -independent mechanisms.[17]
Similar mechanisms of action have been described for sor-
afenib. In particular, Groenendijk et al. demonstrated that
sorafenib, such as metformin, acts as an activator of AMPK
through LKB1 or CAMKK2. The authors reported that
patients with KRAS-mutated advanced NSCLC receiving met-
formin during sorafenib treatment showed better disease con-
trol than those taking sorafenib alone. They also observed a
synergistic growth inhibition of NSCLC cells in vitro and in
vivo with the sorafenib–metformin combination, as well as
synergistic AMPK activation and downstream mTOR path-
way inhibition.[32] Sorafenib would thus seem to use the same
activation pathway as metformin, that is, AMPK.
Conversely, we observed that diabetic patients already
taking metformin before the start of treatment with sorafenib
were more resistant to the multikinase inhibitor than those
with insulin-treated diabetes. A possible explanation for these
contradictory results is that tumors developing during
chronic treatment with metformin are more likely to have
Table 4. Hazard ratio of PFS and OS in diabetic patients receiving metformin or insulin.
PFS OS
HR (95% CI) p HR (95% CI) p
No diabetes 1.00 1.00
Patients with diabetes treated with insulin 0.90 (0.40–2.03) 0.813 0.55 (0.18–1.63) 0.295
Patients with diabetes treated with metformin 2.57 (1.43–4.63) 0.001 2.32 (1.10–4.90) 0.022
HR: hazard ratio; OS: overall survival; PFS: progression-free survival.
Metformin and sorafenib in HCC patients
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intrinsic mechanisms of resistance to metformin, which may
also lead to resistance to sorafenib.
5. Conclusion
In conclusion, although somewhat limited by its retrospective
nature, our study was based on consecutively selected
patients, thus reducing the risk of bias. Findings may be
attributable to increased tumor aggressiveness and resistance
to sorafenib in metformin-treated patients. Molecular char-
acterization of patients will enable us to identify a subset of
HCC patients who are more resistant to sorafenib. We also
plan to validate these data in a prospective study including
non-diabetic patients.
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of both drugs.
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